Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
Details : NUC-3373 (fosifloxuridine nafalbenamide), a new chemical entity derived from the nucleoside analog 5-fluorouracil, continues rapid development with multiple data readouts and dosing of first patients in Phase 3 colorectal cancer study.
Brand Name : NUC-3373
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2022
Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 10 patient out of 37 case studies highlighted NUC-3373’s ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of...
Brand Name : NUC-3373
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 15, 2021
Lead Product(s) : Fosifloxuridine Nafalbenamide,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Encouraging interim data had previously been reported and the final data confirm the high objective response rate and favorable safety profile of Acelarin plus cisplatin in this patient population.
Brand Name : NUC-1031
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2020
Details : NuTide:121 is a global randomized Phase III study of Acelarin that will enroll up to 828 patients in approximately 120 sites across North America, Europe, Asia and Australia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 05, 2020
NuCana Reports Preliminary Data from Phase II Study
Details : The study compared a 500mg/m2 dose of Acelarin versus a 750mg/m2 dose of Acelarin in patients who were heavily pre-treated (at least 3 prior lines of chemotherapy).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2020
Details : Acelarin, in combination with cisplatin, is currently being evaluated in a global Phase III study (NuTide:121) for the first-line treatment of patients with biliary tract cancer.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 05, 2020
Details : The enrollment of patients in NuTide:121 follows U.S. Food and Drug Administration (FDA) clearance of the company's investigational new drug application (IND) for Acelarin.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 27, 2020
LOOKING FOR A SUPPLIER?
Reset All
